Antisense compound for inducing immunological tolerance

Details Antisense compound for inducing immunological tolerance Antisense compound for inducing immunological tolerance

2011-08-30

2011-08-30

McGarry, Sean (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S006120, C536S023100, C536S024100, C514S04400A

Reexamination Certificate

active

08008469

ABSTRACT:
A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.

REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5702891 (1997-12-01), Kolberg et al.
patent: 5733781 (1998-03-01), Ryder et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5849727 (1998-12-01), Porter et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 5955318 (1999-09-01), Simons et al.
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6365351 (2002-04-01), Iversen
patent: 6495663 (2002-12-01), Rothbard
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez et al.
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 7115374 (2006-10-01), Linnen et al.
patent: 7468418 (2008-12-01), Iversen et al.
patent: 2002/0049173 (2002-04-01), Bennett et al.
patent: 2002/0127198 (2002-09-01), Rothbard et al.
patent: 2003/0166588 (2003-09-01), Iversen et al.
patent: 2003/0171335 (2003-09-01), Stein et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2004/0254137 (2004-12-01), Ackermann et al.
patent: 2004/0259108 (2004-12-01), Linnen et al.
patent: 2004/0265879 (2004-12-01), Iversen et al.
patent: 2005/0176661 (2005-08-01), Vaillant et al.
patent: 2005/0203041 (2005-09-01), Mourich et al.
patent: 2005/0234002 (2005-10-01), Mourich et al.
patent: 2006/0149046 (2006-07-01), Arar
patent: 2006/0269911 (2006-11-01), Iversen et al.
patent: 2006/0276425 (2006-12-01), Mourich et al.
patent: 2007/0122821 (2007-05-01), Iversen et al.
patent: 2009/0082547 (2009-03-01), Iversen et al.
patent: 2009/0088562 (2009-04-01), Weller et al.
patent: 2009/0099066 (2009-04-01), Moulton et al.
patent: 2009/0110689 (2009-04-01), Mourich et al.
patent: 2009/0246221 (2009-10-01), Mourich et al.
patent: 2010/0184670 (2010-07-01), Mourich et al.
patent: 0 403 333 (1990-12-01), None
patent: 2647809 (1989-06-01), None
patent: WO 90/07936 (1990-07-01), None
patent: WO 91/05864 (1991-05-01), None
patent: WO 95/05851 (1995-03-01), None
patent: WO 0071706 (2000-11-01), None
patent: WO 01/72765 (2001-10-01), None
patent: WO 2009/086469 (2009-07-01), None
patent: WO 2010/080554 (2010-07-01), None
Irmler et al. (1997) Nature 388(6638):190-5.
Agrawal et al.,“Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.”Proc Natl Acad Sci U S A, 87(4): 1401-5 (1990).
Agrawal et al.,TIBTECH, 14:376-387 (1996).
Agrawal et al.,Molecular Medicine Today, 61:72-81 (2000).
Akhtar, S., et al.,Nucleic Acids Res, 19(20):5551-9 (1991).
Anderson, C. M., et al.,J Neurochem, 73(2):867-73 (1999).
Anderson, K. P., et al.,Antimicrob Agents Chemother, 40(9):2004-11 (1996).
Bonham et al., “An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.”Nucleic Acids Res 23(7): 1197-203 (1995).
Boudvillain et al., “Transplatin-modified oligo(2′-O-methyl ribonucleotide)s: a new tool for selective modulation of gene expression.”Biochemistry, 36(10): 2925-31 (1997).
Branch,TIBS, 23:45-49 (1998).
Braasch et al.,Biochemistry, 41:4503-4510 (2002).
Chen et al.,Bioconjugate Chem., 14:532-538 (2003).
Choudhury, I. et al.,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17(2): 104-111, 1998.
Ding, D., et al.,Nucleic Acids Res., 24(2):354-60 (1996).
Gee, J. E., et al.,Antisense Nucleic Acid Drug Dev., 8(2)103-11 (1998).
Hudziak, R. M., et al.,Antisense Nucleic Acid Drug Dev., 6(4):267-72 (1996).
Loke, S. L., et al.,Proc Natl Acad Sci USA, 86(10):3474-8 (1989).
Micheau,Expert Opin. Ther. Targets, 7:559-573 (2003).
Moulton, H. M., et al.,Antisense Nucleic Acid Drug Dev., 13(1):31-43 (2003).
Moulton, H. M. and J. D. Moulton,Curr Opin Mol Ther., 5(2):123-32 (2003).
Murphy et al.,Science, 250(4988)1720-1723 (1990).
Pari, G. S., et al.,Antimicrob Agents Chemother., 39(5):1157-61 (1995).
Stein, D., et al.,Antisense Nucleic Acid Drug Dev., 7(3):151-7 (1997).
Summerton, J. and D. Weller (1997). “Morpholino antisense oligomers: design, preparation, and properties.”Antisense Nucleic Acid Drug Dev., 7(3):187-95.
Toulme, J. J., R. L. Tinevez, et al. (1996). “Targeting RNA structures by antisense oligonucleotides.”Biochimie, 78(7):663-73.
Wasem et al.,J. Clin. Invest., 111(8):1191-1199 (2003).
Vanin, E.F. and Ji, T.H.,Biochemistry, 20:6754-6760 (1981).
Tung, C. et al.,Bioconjugate Chem., 6:292-295, 1995.
Wender, P. A., et al.,Proc Natl Acad Sci USA, 97(24):13003-8 (2000).
Yakubov, L. A., et al.,Proc Natl Acad Sci USA, 86(17):6454-8 (1989).
Zhu et al.,J. Virology, 76(2):707-716 (2002).
Agrawal et al., “Antisense Therapeutics: Is it as Simple as Complementary Bse Recognition?”,Molecular Medicine Today, 6:72-81 (2000).
Agrawal et al.,“Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus”,Proc Natl Acad Sci U S A, 85(19):7079-7083 (1988).
Agrawal et al.,“Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides”,Proc Natl Acad Sci U S A, 87(4): 1401-5 (1990).
Agrawal, S., “Antisense oligonucleotides: towards clinical trials”,TIBTECH, 14:376-387 (1996).
Akhtar, S., et al., “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)”,Nucleic Acids Res, 19(20):5551-9 (1991).
Anderson, C. M., et al., “Distribution of equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporters (ENT1) in brain”,J Neurochem, 73(2):867-73 (1999).
Anderson, K. P., et al., “Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA”,Antimicrob Agents Chemother, 40(9):2004-11 (1996).
Arora et al., “Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats”,Journal of Pharmaceutical Sciences, 91(4):1009-1018 (2002).
Astriab-Fisher et al., “Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions”,Pharm. Res., 19(6):744-754 (2002).
Bailey, C. P., J. M. Dagle et al., “Cationic oligonucleotides can mediate specific inhibition of gene expression inXenopusoocytes.”Nucleic Acids Res, 26(21): 4860-7 (1998).
Barawkar, D. A. and T. C. Bruice “Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: deoxynucleic guanidine/DNA chimeras&#x

Affiliated with

Also associated with

Rating

Antisense compound for inducing immunological tolerance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense compound for inducing immunological tolerance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense compound for inducing immunological tolerance will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2782152